Peptide therapeutics sales will expand through 2036, with cancer holding 25.3% of the application segment in 2026, driven by steady procurement volumes and standardization across manufacturing applications. The market was valued at USD 46.60 billion in 2025 and is expected to be worth USD 143.99 billion by 2036.